In 2027, Medicare will pay about 21% less for a wound treatment in clinics, but about 15% more at hospitals.

Sanuwave Health (SNWV) announced that Medicare will pay 21% less for its Ultramist therapy in clinics but 15% more in hospitals starting in 2027. The company disputes the clinic payment reduction, citing incomplete data, and plans to engage with CMS. Sanuwave focuses on wound care and regenerative medicine technologies.

Original reporting
Published Nov 5, 2026, 2:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 2:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$SNWV
Bearish
medium confidence
Mentioned
$SNWV
Relevance
5/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$SNWVBearishLow
01

Why it matters

The office-setting payment reduction could compress SNWV's margins, while the hospital outpatient increase may partially offset the impact.

02

Market read

Regulatory change directly affects SNWV's reimbursement rates, creating short-term downside risk.

03

What to watch

Potential for future CMS adjustments or successful lobbying could reverse the cut.

Relevance 5/10Novelty 5/10Timing: post-market today

Background

CMS released its 2027 Physician Fee Schedule and Hospital Outpatient Prospective Payment System rules, adjusting payment rates for CPT code 97610.

Company-level read

Ticker impact

$SNWVBearishMedium confidence
Context

CMS 2027 rule reduces Medicare payment for SNWV's Ultramist therapy in office settings, potentially lowering revenue.

Expected impact

likely downward pressure as market prices in the reimbursement cut.

Evidence & confidence

The payment reduction directly affects SNWV's core product pricing, which may hurt earnings outlook.

Market effects

May signal tighter Medicare reimbursement for advanced wound care devices, affecting peers.

U.S. healthcare reimbursement environment.

Limited to U.S. Medicare policy impact.

Counterpoint

If SNWV can secure alternative payer contracts, the impact may be muted.

Key entities

  • Sanuwave Health, Inc.

    Provider of FDA-cleared directed energy systems for wound care.

  • Centers for Medicare & Medicaid Services (CMS)

    U.S. agency issuing the reimbursement rule.

Related articles

$SNWVMed

Sanuwave Announces Q3 FY2026 Financial Results

SANUWAVE Health, Inc. (SNWV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sanuwave Announces Q3 FY2026 Financial Results Q3 2026 revenues were $8.6 million, down 24% from $11.3 million in Q3 2025. Q3 2026 gross margin was 77.3%, versus 77.6% in Q3 2025. GAAP operating loss was $1.1 million for Q3 2026 versus operating income of $0.9 millio

$SNWVMedAI 8/10

SANUWAVE (SNWV) Q2 2026 Earnings Call Transcript

SANUWAVE (SNWV) reported Q2 2026 revenue of $9.7M, down 3% from $10.1M, driven by lower capital equipment sales. UltraMIST applicator revenue rose 13% to $7.3M, while UltraMIST system revenue fell 34% to $2.3M. The company posted a $0.7M net loss and withdrew FY2026 guidance amid proposed 2027 Medicare reimbursement cuts.

$SNWVMed

Sanuwave Announces Q2 FY2026 Financial Results

SANUWAVE Health, Inc. (SNWV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sanuwave Announces Q2 FY2026 Financial Results Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025. GAAP Operating (Loss) Income was $(0.3) million for Q2 2026 versus $1.4 million in Q2 20

$SNWVMedAI 8/10

What's Going On With SANUWAVE Health Stock On Friday? - SANUWAVE Health (NASDAQ:SNWV)

Sanuwave Health (NASDAQ:SNWV) said it expects Q2 2026 revenue of $9.6 million to $9.8 million, above prior guidance of $8.5 million to $9.5 million. The company noted Q2 revenue is about 3% to 5% lower year over year from $10.1 million. It cited pressured capital sales but record consumable applicator momentum and offered trade-in and support programs. Shares were down 4.44% to $6.36.